Technologiepark Basel
Hochbergerstrasse 60C
Basel 4057
Switzerland
41 61 633 29 71
https://www.kinarus.com
Sektor(en):
Branche:
Vollzeitmitarbeiter:
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Alexander Bausch MTE (IMD), Ph.D. | CEO & Vice Chairman | 291,38k | N/A | 1962 |
Dr. Matthew Wright | COO & Head of Research | 236,16k | N/A | N/A |
Ms. Claudia Berger | Chief Clinical Devel. Officer | 136,73k | N/A | N/A |
Dr. Thierry Fumeaux M.B.A., M.D. | Chief Medical Officer | 136,73k | N/A | N/A |
Stephane Pinto | Head of Investor Relations | N/A | N/A | N/A |
Kinarus Therapeutics Holding AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 mitogen-activated protein kinase inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company was founded in 2017 and is based in Basel, Switzerland.
Curatis Holding AGs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.